Table 5 Univariate and multivariate analysis of factors associated with EFS and OS of all patients.

From: Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study

Clinical characteristics

Event-free survival

Overall survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

P

RR (95% CI)

P

P

RR (95% CI)

P

Gender (female/male)

0.868

  

0.804

  

Age (27–35/18–26 years)

0.025

1.758 (1.003–3.083)

0.049

0.007

2.208 (1.226–3.976)

0.008

Immunophenotype (B/T)

0.470

  

0.894

  

Asparaginase (E. coli-asparaginase/PEG-asparaginase)

0.632

  

0.769

  

ECOG performance status (≥2/0–1 scores)

0.014

1.679 (0.922–3.059)

0.090

0.092

  

Mediastinal mass

0.645

  

0.589

  

Hepatomegaly

0.017

1.052 (0.177–6.235)

0.956

<0.001

1.510 (0.237–9.602)

0.662

Splenomegaly

0.027

1.933 (0.345–10.837)

0.454

0.002

1.907 (0.318–11.441)

0.480

Lymphadenopathy

0.720

  

0.741

  

CR on (day28/day14)

0.003

2.082 (1.208–3.587)

0.008

0.004

1.964 (1.082–3.564)

0.026

  1. Abbreviations: E. coli-asparaginase, Escherichia coli asparaginase; PEG-asparaginase, polyethylene glycol-conjugated asparaginase; CR, complete remission; RR, relative risk. Table.
Back to article page